Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFP-10917 in relapsed/refractory acute leukemia
NCT01702155Phase 2Completed
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Oct 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of radgocitabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by Delta-Fly Pharma, Inc.. Started Oct 2012; status: completed.
02
Drugs
radgocitabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01702155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01702155.